HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 7,537-7,548 of 27,277
Drug study icon
CompletedNCT00791401

Safety study of Pharmacokinetics of ER OROS Paliperidone in Schizophrenia

Official study title

The Pharmacokinetics of ER OROS Paliperidone in Subjects With Varying Degrees of Impaired Renal Function (Mild, Moderate, and Severe) as Compared to Subjects With Normal Renal Function

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–75
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT00791284

Safety study of pharmacokinetics of Paliperidone in Schizophrenia

Official study title

Pharmacokinetics of Paliperidone in Subjects With Moderate Hepatic Impairment as Compared to Subjects With Normal Hepatic Function.

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–75
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Other study type icon
CompletedACTRN12614000429651

The Physical Health and Genetics of PTSD (PTSD).

Official study title

A Cross-Sectional, Case-Control Study of the Physical Health Status of Vietnam Veterans with and without Post-Traumatic Stress Disorder (PTSD) and Investigation of Genetics of PTSD.

This study has finished and is no longer accepting participants.

In Greenslopes
PTSDObservational study
Countries
Australia
Sponsor
Returned Services League (RSL) Queensland
Other study type icon
CompletedNCT03017781

The Relationship of Psychosocial Function With Mood Symptoms in Offspring of Parents With Bipolarity

Official study title

An Observational Longitudinal Study in Offspring of Parents With Bipolar Disorder to Evaluate the Relationship of Impairment in Psychosocial Functioning With the Manifestation of Mood Symptoms Over 24 Months

This study has finished and is no longer accepting participants.

Multiple locations, including Culver City
BipolarityObservational studyAges 15–25
Countries
United States
Sponsor
Janssen Research & Development, LLC
Drug study icon
CompletedNCT00250354

Risperidone or placebo for disruptive behavior in children with intellectual disabilities

About this title

A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation

Read the official source — NCT00250354
Official study title

The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years

This study has finished and is no longer accepting participants.

Location not clearly listed
ADHDMedication studyAges 5–12
Countries
Sponsor
Janssen Pharmaceutica N.V., Belgium
Drug study icon
CompletedNCT00266552

Risperidone or placebo for conduct concerns in children with intellectual disabilities

About this title

A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation

Read the official source — NCT00266552
Official study title

The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years

This study has finished and is no longer accepting participants.

Location not clearly listed
ADHDMedication studyAges 5–12
Countries
Sponsor
Janssen Pharmaceutica N.V., Belgium
Drug study icon
CompletedNCT00132678

Long-acting risperidone to help prevent mood episodes in bipolarity

About this title

A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes

Read the official source — NCT00132678
Official study title

A Randomized, Double-blind, Placebo-controlled Study to Explore the Efficacy and Safety of Risperidone Long-acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-label Extension

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
BipolarityMedication studyAges 18–65
Countries
United States, Austria, India, + 7 others
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT00477672

Pimavanserin or placebo for psychosis in Parkinson disease

About this title

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Read the official source — NCT00477672
Official study title

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

This study has finished and is no longer accepting participants.

Multiple locations, including Gilbert
SchizophreniaMedication studyAges 40+
Countries
United States, France, United Kingdom, + 4 others
Sponsor
ACADIA Pharmaceuticals Inc.
Drug study icon
CompletedNCT02035553

Safety study of safety and Efficacy of Pimavanserin in Schizophrenia

Official study title

A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease

This study has finished and is no longer accepting participants.

In London
SchizophreniaMedication studyAges 50+
Countries
United Kingdom
Sponsor
ACADIA Pharmaceuticals Inc.

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.